Bayer Signs Licensing Agreement With Nagasaki University For Alzheimer’s Diagnosis Compounds
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Bayer Schering Pharma signed a licensing agreement for worldwide development and distribution of diagnostic radioactive tracers made from compounds developed by Nagasaki University to detect Alzheimer's disease, Morio Nakayama, head of research, told PharmAsia News Sept. 17